在常规治疗和阿托伐他汀基础上加用美托洛尔对慢性稳定性冠心病患者的影响OA
Effects of Adding Metoprolol to Conventional Therapy and Atorvastatin in Patients with Chronic Stable Coronary Heart Disease
目的 探讨在常规治疗和阿托伐他汀基础上加用美托洛尔对慢性稳定性冠心病(CHD)患者心绞痛程度、心功能及生活质量的影响.方法 选取2022年1月至2026年1月在兰考县南彰卫生院治疗的慢性稳定性CHD患者200例,采用随机数字表法分为研究组和对照组,每组 100 例.本研究采用开放标签、结局评价者单盲设计.对照组接受阿托伐他汀及常规干预,研究组在对照组基础上加用美托洛尔.比较两组心绞痛严重程度[西雅图心绞痛问卷(SAQ)]、心功能指标、生活质量[健康调查表(SF-36)]及不良反应发生率.结果 治疗 6 个月后,研究组 SAQ 各维度评分均高于对照组,左心室射血分数、每搏输出量、心排血量均高于对照组,左心室收缩末内径、左心室舒张末内径、静息心率均低于对照组,SF-36 各维度评分均高于对照组,差异均有统计学意义(P＜0.05);两组心脏指数比较,差异无统计学意义(P＞0.05);两组不良反应发生率比较,差异无统计学意义(P＞0.05).结论 针对加拿大心血管学会心绞痛(CCS)分级Ⅰ～Ⅱ级的慢性稳定性 CHD 患者,在阿托伐他汀及常规治疗基础上加用美托洛尔可产生增量效益,有助于缓解心绞痛症状并优化部分心功能指标,进而提升患者的生活质量,且未显著增加不良反应发生率.
Objective To investigate the effects of adding metoprolol to conventional therapy and atorvastatin on angina severity,cardiac function,and quality of life in patients with chronic stable coronary heart disease(CHD).Methods A total of 200 patients with chronic stable CHD treated at Nanzhang Health Center of Lankao County from January 2022 to January 2026 were enrolled and randomly divided into a study group and a control group,with 100 patients in each group.This study adopted an open-label design with single blinding of outcome assessors.The control group received atorvastatin combined with conventional interventions,whereas the study group received metoprolol in addition to the treatment provided for the control group.Angina severity[assessed using the Seattle Angina Questionnaire(SAQ)],cardiac function parameters,quality of life[assessed using the Short Form-36 Health Survey(SF-36)],and incidence of adverse reactions were compared between the two groups.Results After 6 months of treatment,all dimensions of the SAQ scores were higher in the study group than in the control group.Left ventricular ejection fraction,stroke volume,and cardiac output were higher,whereas left ventricular end-systolic diameter,left ventricular end-diastolic diameter,and resting heart rate were lower in the study group than in the control group.All dimensions of the SF-36 scores were also higher in the study group than in the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in cardiac index between the two groups(P＞0.05).The incidence of adverse reactions was also not significantly different between the two groups(P＞0.05).Conclusion In patients with chronic stable CHD classified as Canadian Cardiovascular Society(CCS)grade Ⅰ～Ⅱ,adding metoprolol to atorvastatin and conventional therapy provides additional benefits,helping relieve angina symptoms,improve some cardiac function parameters,and enhance quality of life without significantly increasing the incidence of adverse reactions.
李永亮;赵西伦
兰考县南彰卫生院 内科,河南 兰考 475315兰考县南彰卫生院 内科,河南 兰考 475315
冠心病美托洛尔阿托伐他汀心绞痛程度心功能指标
coronary heart diseasemetoprololatorvastatinangina severitycardiac function parameters
《临床研究》 2026 (9)
107-110,4
评论